• br Special report Financial and personal benefits of

  2024-07-09

  

  Special report – Financial and personal benefits of early diagnosis Acknowledgments The Alzheimer’s Association acknowledges the contributions of Joseph Gaugler, Ph.D., Bryan James, Ph.D., Tricia Johnson, Ph.D., Allison Marin, Ph.D., and Jennifer Weuve, M.P.H., Sc.D., in the preparation of 201

• For patients who have taken advantage of the

  2024-07-09

  

  For patients who have taken advantage of the anti-TKIs and whose follow-up has been succeeded, some partial response has been noticed with 45% (9/20) for gefitinib, 39% (9/23) for erlotinib and 56.5% (13/23) for crizotinib. A disease progression has also been observed with 35% (7/20) for gefitinib,

• Unexpectedly under pathological pain conditions inhibition o

  2024-07-09

  

  Unexpectedly, under pathological pain conditions, inhibition of spinal glutamate transporter activity can produce antinociceptive effects. For example, intrathecal injection of the transportable inhibitor trans-pyrrolidine-2,4-dicarboxylic CFTRinh-172 (t-PDC) or antisense oligonucleotides reduced no

• br Transparency document br Introduction G protein

  2024-07-09

  

  Transparency document Introduction G protein-coupled receptors (GPCRs) comprise a diverse family of seven transmembrane domain-containing receptors represented by over 800 genes in humans. GPCRs respond to a range of stimuli, including peptides, hormones, growth factors, lipids, odorants, and

• Moreover our present work suggests

  2024-07-09

  

  Moreover, our present work suggests that AXL could be a modulator of sunitinib response, at least for cell lines that present high endogenous levels of this RTK activation, since we observed an increased responsiveness to sunitinib in Tubastatin A HCl activated with AXL receptor ligand. A role for

• Optimization of the B ring specifically targeted

  2024-07-09

  

  Optimization of the B-ring specifically targeted preventing the oxidation of the ring system (). As described above, the 4-position of the phenyl ring provides the appropriate vector towards bulk solvent. - and -linked substitutions at the 4-position of the B-ring from the 4-fluoro-nitrophenyl inter

• Human lipoxygenase exists in two forms named

  2024-07-08

  

  Human 15-lipoxygenase exists in two forms, named 15-LOX-1 (also named 12/15-LOX, 15-LO-1) and 15-LOX-2. Several reports indicate that 15-LOX-1 has a pathophysiological role in respiratory inflammatory diseases, in particular asthma. Increased activity of 15-LOX-1 is displayed in the respiratory trac

• At the outset of targeting the two Gln

  2024-07-08

  

  At the outset of targeting the two Gln756 side-chain rotamers, it was unclear which rotational isomer would lead to more potent ASK1 inhibitors. While such a preference might have been anticipated, the cohort of ASK1 inhibitors in Table 3 did not provide any guidance regarding which of the Gln756 am

• While increased arginase levels has

  2024-07-08

  

  While increased arginase levels has been shown in animal models and in humans with cardiovascular dysfunction [16], [22], [23], it is unknown whether plasma levels or activity of Arginase may predict ED risk. In addition, recent evidence suggests that plasma l-arginine hydrolysis by arginases limits

• In this study we first determined whether AIF in bovine

  2024-07-08

  

  In this study, we first determined whether AIF in bovine LT muscle is expressed and the mitochondria released AIF-mediated apoptosis during postmortem aging. For apoptotic issues, the mitochondrial outer membrane is permeabilized, and AIF translocates to the cytosol and to the nucleus, where it indu

• The mitochondrial protein AIF was

  2024-07-08

  

  The mitochondrial protein AIF was the first caspase-independent death effector. AIF can induce caspase-independent chromatin condensation and large-scale DNA fragmentation to approximately 50 KB. AIF that is released to cytoplasm can mediate apoptosis when special extracellular signals trigger the o

• br Acknowledgments br Introduction Angiotensin II AngII

  2024-07-08

  

  Acknowledgments Introduction Angiotensin II (AngII) is among the most potent vasoactive substances produced in humans. Its effects are numerous, from vasoconstriction to control of fluid and electrolytes balances. Many of the physiological and pathological effects of AngII are mediated by the

• With wide spread use of corticosteroids to combat inflammati

  2024-07-08

  

  With wide-spread use of corticosteroids to combat inflammation and allergies, even children are susceptible to corticosteroid-induced muscle wasting. Although non-steroidal SGRMs that spare muscle and bone, but have significant anti-inflammatory effects, have been preclinically developed and tested,

• Treatment of RAW cells with AP

  2024-07-08

  

  Treatment of RAW264.7 NVP-ADW742 with AP(+)-exosomes caused an increase in their phagocytic activity. In the presence of amastatin, phagocytic activity was not completely suppressed, suggesting that at least two components were responsible for the activity; one of which is aminopeptidase(s). When t

• Alectinib is a second generation

  2024-07-08

  

  Alectinib is a second generation ALK antagonist that is built upon a 9-ethyl-6, 6-dimethyl-11-oxo benzo[b]carbazole scaffold (Fig. 5C) [58]. This drug is effective against the ALK L1196M gatekeeper mutation along with C1156Y and F1174L mutations [7]. The 11-oxo group of the drug forms a GNE-317 with

15095 records 117/1007 page Previous Next First page 上5页 116117118119120 下5页 Last page